Literature DB >> 19048226

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.

H C Price1, R L Coleman, R J Stevens, R R Holman.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to investigate the impact of using a non-diabetes-specific cardiovascular disease (CVD) risk calculator to determine eligibility for statin therapy according to current UK National Institute for Health and Clinical Excellence (NICE) guidelines for those patients with type 2 diabetes who are at an increased risk of CVD (10 year risk >or=20%).
METHODS: The 10 year CVD risks were estimated using the UK Prospective Diabetes Study (UKPDS) Risk Engine and the Framingham equation for 4,025 patients enrolled in the Lipids in Diabetes Study who had established type 2 diabetes and LDL-cholesterol <4.1 mmol/l.
RESULTS: The mean (SD) age of the patients was 60.7 (8.6) years, blood pressure 141/83 (17/10) mmHg and the total cholesterol:HDL-cholesterol ratio was 3.9 (1.0). The median (interquartile range) diabetes duration was 6 (3-11) years and the HbA(1c) level was 8.0% (7.2-9.0%). The cohort comprised 65% men, 91% whites, 4% Afro-Caribbeans, 5% Asian Indians and 15% current smokers. More patients were classified as being at high risk by the UKPDS Risk Engine (65%) than by the Framingham CVD equation (63%) (p < 0.0001). The Framingham CVD equation classified fewer men and people aged <50 years old as high risk (p < 0.0001). There was no difference between the UKPDS Risk Engine and Framingham classification of women at high risk (p = 0.834). CONCLUSIONS/
INTERPRETATION: These results suggest that the use of Framingham-derived rather than UKPDS Risk Engine-derived CVD risk estimates would deny about one in 25 patients statin therapy when applying current NICE guidelines. Thus, under these guidelines the choice of CVD risk calculator is important when assessing CVD risk in patients with type 2 diabetes, particularly for the identification of the relatively small proportion of younger people who require statin therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048226     DOI: 10.1007/s00125-008-1231-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

1.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer.

Authors:  N Day; S Oakes; R Luben; K T Khaw; S Bingham; A Welch; N Wareham
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

Review 2.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

Authors:  S M Grundy; R Pasternak; P Greenland; S Smith; V Fuster
Journal:  Circulation       Date:  1999-09-28       Impact factor: 29.690

3.  The cerivastatin withdrawal crisis: a "post-mortem" analysis.

Authors:  Marina Maggini; Roberto Raschetti; Giuseppe Traversa; Clara Bianchi; Bruno Caffari; Roberto Da Cas; Pietro Panei
Journal:  Health Policy       Date:  2004-08       Impact factor: 2.980

4.  Mortality trends in men and women with diabetes, 1971 to 2000.

Authors:  Edward W Gregg; Qiuping Gu; Yiling J Cheng; K M Venkat Narayan; Catherine C Cowie
Journal:  Ann Intern Med       Date:  2007-06-18       Impact factor: 25.391

5.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

6.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

7.  Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial.

Authors:  Andrew Farmer; Alisha Wade; Elizabeth Goyder; Patricia Yudkin; David French; Anthea Craven; Rury Holman; Ann-Louise Kinmonth; Andrew Neil
Journal:  BMJ       Date:  2007-06-25

8.  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

Authors: 
Journal:  Diabetologia       Date:  1991-12       Impact factor: 10.122

9.  Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study.

Authors:  R Hiller; R D Sperduto; M J Podgor; F L Ferris; P W Wilson
Journal:  Am J Epidemiol       Date:  1988-08       Impact factor: 4.897

10.  Unrealistic pessimism about risk of coronary heart disease and stroke in patients with type 2 diabetes.

Authors:  Koula G Asimakopoulou; T Chas Skinner; Jennifer Spimpolo; Sally Marsh; Charles Fox
Journal:  Patient Educ Couns       Date:  2008-02-19
View more
  2 in total

1.  Diabetes: Which risk engines should be used to assess patients with diabetes?

Authors:  Kausik K Ray; Naveed Sattar
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

2.  Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil.

Authors:  Marilia B Gomes; Daniel Giannella-Neto; Manuel Faria; Marcos Tambascia; Reine M Fonseca; Rosangela Rea; Geisa Macedo; João Modesto-Filho; Helena Schmid; Alcina V Bittencourt; Saulo Cavalcanti; Nelson Rassi; Hermelinda Pedrosa; Sergio A Dib
Journal:  Diabetol Metab Syndr       Date:  2009-10-27       Impact factor: 3.320

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.